Non-viral GMP manufacturing for engineered cells at clinical and commercial scale

Advancements in Electroporation: Enhancing Gene-Modified Cell Therapy for Scalability and Efficacy

Continuous Flow Transfection With Flowfect Technology As An Efficient, Non-Viral Technology For Scalable, Crispr-Mediated Engineering Of Primary T-Cells

Enhancing Non-viral Engineering of Cells for Cell Therapy Manufacturing ​- Optimizing Yields for Peak Cell Quality with the Flowfect Tx™ Platform

Machine Learning Approach To DNA Transfection Optimization Of Primary T Cells Using Flowfect® Technology

Continuous Flow Transfection With Flowfect® Technology Enables Rapid Optimization And Scale-Up For Efficient Co-Delivery Of mRNA And Plasmid DNA In Primary Human T Cells

A Non-viral Pathway to GMP Manufacture Engineered Cell Therapies – Maximizing Yields of Highest Quality Cells

Optimization and characterization of donor-to-donor variability of primary natural killer cells transfected with RNP

Delivery of mRNA and CRISPR-Cas9 RNP to primary Natural Killer cells and T cells using Flowfect®, a new transfection technology

Electro-mechanical transfection for non-viral primary immune cell engineering

CRISPR-Cas9 RNP Editing of Primary T Cells Using the Flowfect® Transfection Technology Platform

CRISPR-Cas9 RNP editing of primary T cells using the Flowfect® transfection technology platform

Flowfect® Transfection of iPSCs Maintains Cell Pluripotency

Flowfect®: A scalable non-viral delivery process for T cell engineering

Microfluidic Screening of Electric Fields for Electroporation